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Abstract
Background: Radical surgery is the cornerstone in the treatment of resectable gastric cancer. The Intergroup 0116
and MAGIC trials have shown benefit of postoperative chemoradiation and perioperative chemotherapy,
respectively. Since these trials cannot be compared directly, both regimens are evaluated prospectively in the
CRITICS trial. This study aims to obtain an improved overall survival for patients treated with preoperative
chemotherapy and surgery by incorporating radiotherapy concurrently with chemotherapy postoperatively.
Methods/design: In this phase III multicentre study, patients with resectable gastric cancer are treated with three
cycles of preoperative ECC (epirubicin, cisplatin and capecitabine), followed by surgery with adequate lymph node
dissection, and then either another three cycles of ECC or concurrent chemoradiation (45 Gy, cisplatin and
capecitabine). Surgical, pathological, and radiotherapeutic quality control is performed. The primary endpoint is
overall survival, secondary endpoints are disease-free survival (DFS), toxicity, health-related quality of life (HRQL),
prediction of response, and recurrence risk assessed by genomic and expression profiling. Accrual for the CRITICS
trial is from the Netherlands, Sweden, and Denmark, and more countries are invited to participate.
Conclusion: Results of this study will demonstrate whether the combination of preoperative chemotherapy and
postoperative chemoradiotherapy will improve the clinical outcome of the current European standard of
perioperative chemotherapy, and will therefore play a key role in the future management of patients with
resectable gastric cancer.
Trial registration: clinicaltrials.gov NCT00407186
Background
In the Western world, most patients with gastric cancer
present with advanced stages of disease, leading to a low
5-year survival of around 25% [1,2]. After surgical resec-
tion, the majority of patients will develop a locoregional
recurrence [3]. Many different strategies have been eval-
uated to improve the outcome of gastric cancer surgery.
Randomized trials investigating the role of a more
extended lymph node dissection (D2) in comparison
with the standard D1 lymphadenectomy, found no dif-
ference in overall survival, while a D2 dissection was
associated with increased postoperative mortality and
morbidity [4-7].
Two Western studies have changed current clinical
practice in the treatment of resectable gastric cancer.
The Intergroup 0116 study showed a significant benefit
in overall survival with adjuvant chemoradiotherapy
( C R T )c o n s i s t i n go f4 5G yo fr a d i o t h e r a p yc o m b i n e d
with fluorouracil (5-FU), and leucovorin, compared to
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Research Council Adjuvant Gastric Infusional Che-
motherapy) study, a significant overall survival benefit
was found favouring perioperative chemotherapy (epiru-
bicine, cisplatin, and continuous 5-FU infusion, ECF-
regimen) versus surgery alone [9].
Taken the abovementioned pivotal studies together,
the important question that needs to be answered is
whether postoperative chemoradiotherapy improves sur-
vival as compared to postoperative chemotherapy in
patients who are treated with neoadjuvant chemotherapy
followed by gastric resection. Due to differences in study
design and eligibility criteria between the Intergroup
0116 and the MAGIC study, comparing results of these
trials is intrinsically not possible (Table 1). Therefore,
the two regimens should be compared in a prospective,
randomized manner. This is performed in the currently
accruing CRITICS trial (ChemoRadiotherapy after
Induction chemoTherapy In Cancer of the Stomach). In
t h ep r e s e n tm a n u s c r i p t ,w ed e s c r i b et h es t u d yp r o t o c o l
of this trial and reflect on the possible implications.
Methods/design
Study design and objectives
The CRITICS study is an international, multicentre, ran-
domized phase III trial. The primary objective is to
compare overall survival between patients treated with
neoadjuvant chemotherapy followed by surgery and
either postoperative chemotherapy or postoperative che-
moradiotherapy for resectable gastric cancer (Figure 1).
Secondary endpoints include disease-free survival, toxi-
city, health-related quality of life (HRQL), prediction of
response and recurrence risk assessed by genomic and
expression profiling. Randomization is performed
directly after entering the study, before the administra-
tion of preoperative chemotherapy.
The study started in January 2007 and as of May 2011,
350 patients have been included, while a total of 788 is
required to meet the H0 hypothesis that the experimen-
tal arm with adjuvant chemoradiotherapy improves OS
by 10% or more. In the first two years only a few cen-
tres in the Netherlands included patients in this trial. At
current times, about 50 centres are collaborating, and,
besides the Netherlands, Sweden and Denmark are par-
ticipating countries (clinicaltrials.gov NCT00407186).
Patient selection and preoperative staging
Patients with histologically proven stage Ib-IVa (AJCC
6
th edition) gastric adenocarcinoma are eligible for this
study. The gastro-oesophageal junction (GEJ) may be
involved, but the bulk of the tumour has to be in the
stomach. Patients should be at least 18 years old and
WHO performance status should be 0 or 1. Patients
must have adequate haematological, renal and liver
functions as defined in the study protocol. Left ventricu-
lar ejection fraction should not be lower than 50%.
Exclusion criteria include: previous malignancy, inop-
erability due to technical surgery-related factors or gen-
eral condition, and a solitary functioning kidney within
the potential radiation field.
Baseline investigations consist of blood tests, an oeso-
phagogastroduodenoscopy with tumour biopsy samples,
computed tomography (CT) of the chest and abdomen,
renography, cardiac ejection-fraction scan, electrocardio-
graphy, and when the preoperative CT-scan suggests
peritoneal carcinomatosis, diagnostic laparoscopy. Endo-
scopic ultrasonography and a PET-scan are optional.
Randomization is performed with stratification for
Lauren classification (intestinal, diffuse, or mixed type
adenocarcinoma, or unknown), localization (GEJ, proxi-
mal, mid, or distal stomach) and hospital.
Preoperative chemotherapy
Within two weeks after randomization, preoperative
chemotherapy is started. All patients are treated with 3
cycles of epirubicin, cisplatin, and capecitabine (ECC).
Epirubicin 50 mg/m
2 and cisplatin 60 mg/m
2 are admi-
nistered on day 1 intravenously every three weeks, with
adequate hydration. Capecitabine is given orally on days
1-14 in a dose of 1000 mg/m
2 bid. In Sweden, oxalipla-
tin 130 mg/m
2 is administered instead of cisplatin in
order to facilitate chemotherapy administration in the
outpatient clinic setting without the need for prehydra-
tion. At the start of the study no reimbursement was
available for oxaliplatin in the treatment of gastric can-
cer in the Netherlands.
Response evaluation with CT-scan after two cycles of
chemotherapy is aimed primarily to identify patients
with early progression.
Surgery
Surgery is planned 3-6 weeks after the last chemother-
apy course. The definitive decision to proceed to surgery
is taken based on the absence of signs of progressive
disease and an ASA classification of 1 or 2.
Under general anaesthesia supported by epidural
anaesthesia, a midline laparotomy is performed, followed
by a complete exploration of the abdomen including
peritoneal surfaces, liver, and in women, the ovaries.
Any free abdominal fluid is aspirated for cytological
examination. A curative resection is not possible in case
of tumour infiltration into the head of the pancreas
requiring a Whipple procedure, para-aortic lymph node
metastases below the renal arteries, tumour positive
cytology of free peritoneal fluid, or peritoneal metastases
that cannot be included in the planned local resection.
If curative resection is not possible, the best palliative
surgical option is to be decided upon by the surgeon.
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Page 2 of 8Table 1 Comparison of Intergroup 0116, MAGIC and CRITICS trials
Intergroup 0116[8] MAGIC[9] CRITICS
General
Accrual 1991 - 1998 1994 - 2002 2007 -
Number of patients 556 503 788 (needed)
Randomization after R0 surgery after diagnosis
(before any treatment)
after diagnosis
(before any treatment)
Inclusion
Histology Adenocarcinoma Adenocarcinoma Adenocarcinoma
Location GOJ/Stomach Lower 1/3 oesophagus/GOJ/
Stomach
GOJ (bulk tumour in stomach)/Stomach
Stage IB-IV (M0) II-IV (M0) IB-IV (M0)
Preoperative Therapy
Preoperative therapy not applicable A: ECF (3 courses)
B: none
A: ECC/EOC (3 courses)
B: ECC/EOC (3 courses)
Completed preoperative
therapy
not applicable 86% ongoing
Surgery
Surgery D0 gastrectomy: 54%
D1 gastrectomy: 36%
D2 gastrectomy: 10%
oesophagogastrectomy: 23%
D1 gastrectomy: 19%
D2 gastrectomy: 40%
non-curative/unknown: 18%
ongoing
R0 resection 100%
(if R1/R2: no inclusion)
A: 69.3%
B: 66.4%
ongoing
Postoperative Therapy
Postoperative Therapy A: 5-FU/LV/RT (45Gy)
B: none
A: ECF (3 courses)
B: none
A: CC/RT (45Gy)
B: ECC/EOC (3 courses)
Completed postoperative
therapy
64% 42% ongoing
Quality Assurance
Surgery D2 recommended
Postoperative analysis of extent of LN
dissection
not reported D1+ resection
Regular feedback to individual surgeons and
pathologists
Radiotherapy Central review of RT plan
Major deviations corrected
not applicable Central review of at least first 3 RT plans of
each center
CTV contouring atlas available
Results
Primary endpoint Overall Survival Overall Survival Overall Survival
Result primary endpoint
(experimental versus
control)
A: 42% 5-year OS
B: 25% 5-year OS
A: 36% 5-year OS
B: 23% 5-year OS
ongoing
A: experimental arm
B: control arm
GEJ: gastro-oesophageal junction
5-FU: 5-fluorouracil
LV: leucovorin
RT: radiotherapy (always 25 × 1.8 Gy in 5 weeks)
CC: capecitabine/cisplatin
ECC: epirubicin/cisplatin/capecitabine
EOC: epirubicin/oxaliplatin/capecitabine
CTV: clinical target volume
GOJ: gastro oesophageal junction
OS: overall survival
D1+ resection: removal of stations 1-9 and 11, at least 15 lymph nodes, no routine splenectomy
R0: microscopically radical
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bearing part of the stomach (total, subtotal or distal gas-
trectomy) en bloc with the N1 and N2 lymph nodes
(stations 1-9 and 11, Figure 2) [10] with a minimum of
15 lymph nodes, without routine splenectomy and
resection of the pancreatic tail (D1+ lymph node dissec-
tion). If possible, a macroscopic proximal and distal
margin of 5 cm should be obtained. Adjacent organs are
only removed when there is suspicion on tumour
involvement.
The continuity of the gastrointestinal tract is restored
by a Billroth II reconstruction or with the use of a
Roux-en-Y loop. Whether the anastomosis is hand-
sutured or stapled is left up to the surgeon. A feeding
jejunostomy is strongly advocated and is left in situ
until postoperative treatment has been completed and
oral intake is adequate.
Pathology
The specimen is sent to the pathologist, preferably fresh
and unopened to enable the collection of fresh frozen
tissue, followed by processing and reporting of the spe-
cimen according to the study protocol. The pathology
report includes a minimal dataset containing the follow-
ing items: type of tumour, localization and size of
tumour, invasion depth, surgical margins, and number
of (tumour positive) lymph nodes. All specimens
undergo additional central pathology review for grading
of histological response [11].
Postoperative treatment
Between 4-12 weeks following surgery, patients in the
control arm are given another 3 courses of ECC.
Patients in the experimental arm are treated with radio-
therapy combined with capecitabine and cisplatin during
five weeks. Capecitabine in this group is administered in
ad o s eo f5 7 5m g / m
2 b i df r o mM o n d a yt oF r i d a y .C i s -
platin is administered at a dose of 20 mg/m
2 intrave-
nously with pre- and posthydration weekly. The
chemotherapy doses are based on previous dose-finding
studies in The Netherlands Cancer Institute [12,13] (see
discussion).
Figure 1 Randomization scheme. R: randomization. ECC: epirubicin, cisplatin, capecitabine.
Figure 2 Lymph node stations as defined by the Japanese Research Society for Gastric Cancer. right cardial nodes 1. left cardial nodes. 2.
along the lesser curvature. 3. along the greater curvature. 4. suprapyloric nodes. 5. infrapyloric nodes. 6. along the left gastric artery. 7. along the
common hepatic artery. 8. around the celiac axis. 9. at the splenic hilum. 10. along the splenic artery. 11. in the hepatoduodenal ligament. 12.
dorsal to the pancreatic head. 13. at the root of the mesentery. 14. in the traverse mesocolon. 15. para-aortic nodes.
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Gy with a frequency of five fractions a week. External
beam therapy is used to irradiate the tumour bed, ana-
stomoses and regional lymph nodes. The clinical target
volume (CTV) has to be delineated on CT-images based
on all diagnostic information available.
In defining a planning target volume (PTV), the CTV
has to be expanded in all directions with a margin of 10
mm, except towards the vertebrae and kidneys, where a
margin of 5 mm is applied. All 3D conformal (or IMRT,
intensity modulated radiotherapy)t e c h n i q u e sa r e
allowed to get a homogeneous dose distribution in the
PTV. AP-PA techniques are judged to be suboptimal
and are therefore not allowed.
Target volume delineation manuals and workshops are
offered to all participating radiation oncologists. A digi-
tal CTV contouring atlas is made available for all local
investigators by the study coordinators. Furthermore, all
centres are asked to provide CTV contouring and treat-
ment plans of the first three included patients (or of
consecutive patients if considered necessary) to the
study coordinators before start of treatment, as interob-
server variability in CTV delineation for postoperative
radiotherapy after gastric resection is large [14].
Toxicity and adverse events
Toxicity is measured according to NCI Common Toxi-
city Criteria (CTC), version 3.0. When preoperative che-
motherapy is postponed for more than two weeks
consecutively, chemotherapy should be discontinued
and the patient should proceed to surgery when possi-
ble. Dose modification rules are defined in the study
protocol [15].
Serious adverse events are defined according to the
rules of good clinical practice and must be reported
within one working day.
Follow-up
After treatment, patients are followed by a medical
oncologist or gastroenterologist (and radiation oncolo-
gist when they received radiotherapy) on a monthly
basis during the first three months, followed by three-
monthly visits during the rest of the first year and visits
every six months until five years of follow-up. Beyond
the initial postoperative period, follow-up by the sur-
geon is planned every 6 months. CT-scanning and reno-
graphy is performed every 6 months, followed by yearly
scans after 2 years of follow-up.
Statistics
Based on results from the Intergroup 0116 [8] and
MAGIC [9] trials, it is estimated that 5-year overall sur-
vival in the perioperative chemotherapy group is 40%
and in the chemoradiotherapy group 50%. In order to
detect a difference between 40% and 50% in 5-year over-
all survival with a power of 80% and a significance level
of 0.05, about 430 events are required, which corre-
sponds to a total of 788 patients.
Data analysis will be performed according to the
intention to treat principle.
An interim analysis is performed when half of the
required number of events have been observed.
Ethics
All patients receive both oral and written information
about the study. Randomization can only take place
when patients have signed an informed consent. The
study is carried out in agreement with the declaration of
Helsinki. The study has been approved by the Medical
Ethical Committee of the Netherlands Cancer Institute -
Antoni van Leeuwenhoek Hospital.
Quality assurance
Local monitoring has been performed for the first three
patients in the first ten participating centres and conti-
nuation of the monitoring will be performed.
Furthermore, surgical and pathological quality is mon-
itored for every patient, and feedback to the individual
surgeons and pathologists on their own performance is
used to improve surgical and pathological quality.
Side studies
Patients fill out quality of life questionnaires EORTC
QLQ-C30 and STO22 five times after randomization:
before treatment, after preoperative chemotherapy, after
surgery, after postoperative therapy and during follow-
up after 12 months.
After finishing accrual and survival analysis, the value
of the Maruyama Index of unresected disease [16] and
the Memorial Sloan-Kettering Cancer Center (MSKCC)
predictive nomogram [17] will be investigated. Further-
more, collected tumour tissue and serum will be used
for genomic profiling and further translational research
focussing on prognostic and predictive biomarkers.
Discussion
Surgery
In both the British MRC trial [4,5] and the Dutch Gas-
tric Cancer Trial (DGCT) [6,7] that randomized gastric
cancer patients for a D1 or D2 lymph node dissection,
overall survival was not statistically different between
the two groups, while a D2 dissection was associated
with increased postoperative mortality and morbidity.
This might be partially attributed to the higher number
of splenectomies and pancreatectomies with a D2 dis-
section. Another study showed that splenectomy is asso-
ciated with a twofold risk of postoperative
complications [18].
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omy with dissection of at least 15 (N1 and N2) lymph
nodes, but without routine splenectomy and resection of
the pancreatic tail, a so called D1+ resection, can result
in a better outcome [19]. The rationale for a minimum
of 15 nodes has been the observation that patients with
at least 15 nodes examined have superior survival as
compared to patients with fewer nodes examined [20,21].
While the Intergroup 0116 study, which had no strict
surgical quality protocol, was criticized for its low num-
ber of per protocol prescribed D2 dissections [16], in
the MAGIC study the percentage of D2 dissections was
higher, although no surgical or pathological quality mea-
surements were performed. In the CRITICS study, the
Maruyama Index (MI) of unresected disease is used to
estimate surgical quality [16]. Also, feedback to indivi-
dual surgeons and pathologists on their own perfor-
mance is used to improve surgical and pathological
quality.
Postoperative chemoradiotherapy
T h eI n t e r g r o u p0 1 1 6s t u d yi st h ek e yt r i a ls u p p o r t i n g
the use of postoperative chemoradiotherapy in the
potentially curative treatment of gastric cancer [8].
Because of this trial, postoperative CRT is currently a
standard option in the United States for patients under-
going curative resection of stage Ib-IV gastric can-
cer [22]. However, the study has been criticized because
it had no strict surgery and pathology quality protocol,
suboptimal surgery (with 54% D0 resections while at
least a D1 resection should be recommended), a com-
plex, toxic and nowadays outdated chemotherapy sche-
dule with minimal room for interaction with the daily
radiation sessions, and the fact that patients were highly
selected (only R0 resections with adequate postoperative
recovery). In addition, toxicity in the chemoradiotherapy
arm was substantial, with only 64% of the patients com-
pleting the planned treatment. In a Dutch retrospective
study, postoperative chemoradiation after a D2 dissec-
tion was not associated with improved survival [23], in
contrast to the results of a large observational Korean
study [24].
Since the Intergroup 0116 study was initiated in the
early 90s, the concept of concurrent chemoradiotherapy
has nowadays been further developed. Capecitabine, an
oral prodrug of 5-FU, mimics continuous infusion of 5-
FU, and has proven its feasibility in combination with
cisplatin and radiotherapy in several phase I/II studies
in advanced, resectable gastric cancer [12,25], while its
systemic exposure was not found to be compromised by
the radiation treatment [26]. In these studies, acute toxi-
city was low, and compliance to the treatment protocol
was high (89-100%). The maximum tolerable doses that
evolved from these studies are currently used in the
CRITICS study. Renal toxicity was addressed in a pro-
spective fashion, showing a reduction in contribution of
the left kidney to total renal function in more than half
of the patients, especially after 2D radiotherapy techni-
ques [27]. This illustrates the need for precise modern
radiotherapy techniques to minimize renal toxicity.
Chemotherapy
Many studies have been performed with adjuvant che-
motherapy in resectable gastric cancer. These studies
have been part of several meta-analyses, which could
demonstrate no, or at the most a modest survival benefit
for adjuvant chemotherapy [28-33]. Newer chemother-
apy schedules, with capecitabine and oxaliplatin, have
shown to be as least as effective as schedules with 5-FU
and cisplatin, with respect to overall survival (REAL-2
study) [34].
The combination of adjuvant with neo-adjuvant che-
motherapy has proven its value in two randomized stu-
dies. In the MAGIC study, perioperative chemotherapy
resulted in a reduction of the tumour stage, a 10%
higher resectability rate and a significant survival benefit
of 13% at 5 years [9]. It should be noted that only 55%
started postoperative chemotherapy and 42% of the
patients completed the entire treatment. The major rea-
sons for a premature treatment stop were tumour pro-
gression, postoperative complications, patients’ refusal
and toxicity. A French prospective trial showed compar-
able results with 48% of the patients completing the
total regimen [35]. The final report of this study has to
be awaited. A recent EORTC study comparing preopera-
tive chemotherapy and D2 surgery with D2 surgery
alone was stopped early because of poor accrual. A
higher R0 resection rate was found in the chemotherapy
arm, but no benefit in survival was detected in this
underpowered study [36].
Due to the strong position of perioperative che-
motherapy with tumour downsizing and downstaging
the CRITICS investigators were reluctant towards a ran-
domization arm without preoperative chemotherapy.
Therefore, both arms have the same preoperative che-
motherapy schedule. This also leads to comparable
resection rates thus eliminating the effect of surgery
(and preoperative therapy) on a potential survival differ-
ence between the two treatment arms.
Future perspectives
With the CRITICS trial, several other studies on the
treatment of resectable gastric cancer are ongoing or
have just finished. In the currently accruing MAGIC-B
study, patients are randomized between perioperative
ECC courses with or without bevacizumab. In the Kor-
ean ARTIST trial, which finalized accrual, patients were
randomized between postoperative chemotherapy with
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after a D2 gastric resection. No preoperative therapy
was administered. Feasibility data of this study were
reported at ASCO-GI 2009 showing good toxicity pro-
files with compliance rates of 75% versus 82% respec-
tively. Survival data of this trial have to be awaited [37].
An interesting development is the use of trastuzumab
for Her2 positive tumours, which has shown an impress-
ive survival benefit in metastasized gastric cancer [38].
This raises the question if trastuzumab is a valuable
addition to the currently used chemotherapy regimens
for Her2 positive, resectable gastric cancer. But so far,
no such trials have been initiated.
Final remarks
Accrual for the CRITICS study has been expanded to
Sweden and Denmark and more countries are invited to
participate. It is expected that the results of this study
will play a key role in the future treatment of patients
with resectable gastric cancer [39].
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